Overview

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Status:
Active, not recruiting

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open label study to assess the safety and pharmacokinetics of YKP3089 as adjunctive therapy in subjects with partial onset seizures. Initially, subjects taking phenytoin or phenobarbital will be enrolled followed by additional subjects taking anti-epileptic drugs other than phenytoin and phenobarbital to further investigate long-term safety.

Phase:

Phase 3

Details

Lead Sponsor:

SK Life Science
SK Life Science, Inc.

Treatments:

Cenobamate